Cell-Based Flavivirus Infection (CFI) Assay for the Evaluation of Dengue Antiviral Candidates Using High-Content Imaging
- 20 February 2014
- book chapter
- Published by Springer Nature
- Vol. 1138, 99-109
Abstract
Large-scale screening of antiviral compounds that target dengue virus life cycle requires a robust cell-based assay that is rapid, easy to conduct, and sensitive enough to be able to assess viral infectivity and cell viability so that antiviral efficacy can be measured. In this chapter we describe a method that uses high-content imaging to evaluate the in vitro antiviral efficacy in a modification to the cell-based flavivirus immunodetection (CFI) assay that was described previously in Wang et al. (Antimicrob Agents Chemother 53(5):1823–1831, 2009).Keywords
This publication has 7 references indexed in Scilit:
- The global distribution and burden of dengueNature, 2013
- Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse modelAntiviral Research, 2011
- A Small-Molecule Dengue Virus Entry InhibitorAntimicrobial Agents and Chemotherapy, 2009
- Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue VirusesViral Immunology, 2008
- Cell-based assays to identify inhibitors of viral diseaseExpert Opinion on Drug Discovery, 2008
- Prospects for a dengue virus vaccineNature Reviews Microbiology, 2007
- A cell-based luminescence assay is effective for high-throughput screening of potential influenza antiviralsAntiviral Research, 2007